PPT-Her2 + Breast Cancer Laura

Bidstrup Mrs B is a 49 yo woman who attended for a regular 3 weekly review and Herceptin dose Intro Dec 2000 attended GP regarding lump that had been present in L breast for 612 Bx breast ca. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Monica Brown, MPH, PhD. . California Cancer Registry. Mary Paré, RN, BS. . Sutter Cancer Center, Sacramento. Katrina Bauer, MS, CTR. . California Cancer Registry. NAACCR 2009 Conference, June 13-19, San Diego. Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Mohammad . Jahanzeb. , MD, FACP. Professor of Clinical Medicine, Hematology-Oncology. Director, UM Sylvester Deerfield Campus. Associate Center Director for Community Outreach. Sylvester Comprehensive Cancer Center. Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer across the breast cancer therapy spectrum. Phase I. Phase II. Phase III. Registration. Approval. HER2+ Breast Cancer. Extended adjuvant. Neratinib monotherapy. Metastatic. Monotherapy or combination therapy. Triple-Negative Breast Cancer. Jamie Carroll, APRN, MSN, CNP. Hope S . Rugo. , MD. . Disclosures for . Ms. Carroll. No financial interests or affiliations to disclose. Disclosures for Dr . Rugo. Contracted Research. Heather M. Gage, MD, Avanti . Rangnekar. , Robert E. Heidel, . PhD. , Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, . PhD. The Graduate School of Medicine. The Department of Pathology. Introduction. A. University of Tennessee Medical Center – Knoxville. Departments of Pathology, Surgery, and Medicine. BREAST CANCER IN YOUNG AGE (≤40 YEARS): THE UNIVERSITY OF. . TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE. in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor . of Breast Oncology . & Professor of Medicine. ishtiaq. . FCPS R3 general surgery unit one UKSO . prof . tariq. . ghaffor. . sb. . . Objectives. Surgical Anatomy. Investigations. Diagnosis. Dr. Vicente Marco. Department of Pathology. Hospital . Quiron. Barcelona. Spain. Second Opinion in Breast Pathology. Usually requested when a patient is referred from another institution for treatment.